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were females. The mean age and Charlson Co-morbidity Index
score were higher among patients who received INF compared
to those on ETA. All-cause PPPM costs were higher among
patients who received ETA ($6320) compared to patients who
received INF ($2313). The magnitude of the difference was
greater among patients who received INF alone ($3368) com-
pared to ETA alone ($8257, p < 0.05). Differences in total health
care costs persisted after adjustment for covariates (p = 0.0366).
Similar results were obtained when excluding outlier patients
with high cost (outliers were deﬁned as those patients with values
more than 2 standard deviations above the mean). CONCLU-
SION: This study indicates that INF therapy is associated with
lower all cause health care costs compared to ETA therapy, in
the treatment of patients with PsA. The choice of a biologic treat-
ment on health care costs should be considered when evaluating
treatment strategies.
PAR7
EVALUATION OF PHARMACOLOGIC TREATMENTS OVER 30
MONTHS FOR OSTEOARTHRITIS USING A NATIONAL
MANAGED CARE DATABASE
Kozma C1, Dickson M2, Janagap C3, Schein JR3
1Independent Consultant, West Columbia, SC, USA, 2University 
of South Carolina, College of Pharmacy, Columbia, SC, USA,
3Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Raritan, NJ, USA
OBJECTIVES: To evaluate trends in utilization and cost of phar-
macologic treatments of osteoarthritis (OA). METHODS: A ret-
rospective analysis of OA patients (>18 years of age) in the
PHARMetrics database during 2001 and 2002 was conducted
using an observation period (January 2003–June 2005) divided
into ten quarters. Patients were retained if they had continuous
eligibility, at least two OA diagnoses, OA drug use during the
observation period, no cancer, HIV or organ transplant, and were
not in a nursing home. The percentage of days of drug availabil-
ity, proportion of patients and cost were evaluated by type of pain
treatment and adjunctive therapy (i.e., ulcer medications, hyp-
notics, and antidepressants). Patients’ treatments were assessed
at the ﬁrst quarter and followed through the tenth quarter.
Random coefﬁcient models for utilization and cost outcomes were
evaluated, by treatment, using mixed model analysis of variance.
RESULTS: Eligible patients (N = 9972) were, on average, 55.1
years old (SD 9.7) and 65.6% were female. Common comor-
bidities included endocrine or immunity disorders (71.9%),
hypertension (59.0%), and obesity (17.6%). At the end of 30
months, the percent change in the number of subjects using COX-
2s and NSAIDs indicated a reduction of 76% and 10%, respec-
tively. Individual growth models on utilization and cost for
COX-2 (p < 0.001) conﬁrmed the trend. Among NSAID users,
35% used 2 or more different NSAIDs and 18.1% of these had
an average time between NSAID switches of 90 days or less. Nar-
cotics showed a signiﬁcant increasing trend in percentage of days
use and costs (p < 0.001). CONCLUSION: Trends over 30
months suggest, increasing narcotic use, high discontinuation of
COX-2s, and a high proportion of NSAID patients with switches
within 90 days. No single dominant therapy over time appeared
in this study suggesting there is a potential for new approaches
and reconsiderations for OA treatment.
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OBJECTIVES: While health care providers ﬁnd PRO data valu-
able for managing patients’ care, they also see a need for more
patient involvement. This research was conducted to gather
input from patients and providers about the value of health out-
comes data for patients in the area of rheumatoid arthritis with
or without psoriasis. METHODS: We conducted follow-up tele-
phone interviews with a sample of 50 individuals (27 physicians,
11 nurses, 12 patients) who participated in one of two programs
associated with rheumatoid arthritis. The programs were
designed to provide patient feedback about experiences with a
given prescription medication to physicians via one-page graph-
ical reports. The semi-structured interviews included questions
regarding providers’ impressions of the feedback and its value
for patients. Patients were asked about the program and the
value of feedback for them. This qualitative analysis summarizes
their responses. RESULTS: Of the 27 physicians interviewed,
56% (n = 15) were dermatologists and 44% (n = 12) rheuma-
tologists. Eleven nurses from dermatology practices and 12
patients with rheumatoid arthritis were interviewed as well. Par-
ticipants were in general agreement that the feedback was useful
for monitoring patients’ responses to treatment, when viewed in
conjunction with clinical observations. Many providers stated
that they could show the feedback to the patient, “in black and
white”, and begin a discussion. Most patients report participat-
ing in the programs because they want their physicians to receive
the feedback. Many patients also expressed an interest in receiv-
ing the feedback themselves to track their progress, indepen-
dently and relative to other patients. A few physicians echoed
this sentiment, stating that through the feedback patients could
feel connected and that may increase involvement in their care.
Providers however, emphasized that the information be provided
in “patient-friendly” terms. CONCLUSION: Based on this
research, a new audience for health outcomes data—delivered in
simple, straightforward terms—is patients themselves.
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OBJECTIVES: Assess impact of high patient out-of-pocket
expenditures (OOP) on adherence and persistence with biolog-
ics for treatment of RA. METHODS: An incidence cohort of RA
patients with pharmacy claims for etanercept or adalimumab
during 2002–2003 was selected from a database of insurance
claims from self-insured employer health plans (N = 2311).
Adherence was deﬁned as the medication possession ratio
(MPR), proportion of the 365 days follow-up covered by days
supplied. Persistence was determined using a survival analysis of
the likelihood of discontinuing therapy. Patient’s OOP was mea-
sured in two ways: 1) patient’s coinsurance and co-payments per
week of therapy, and 2) proportion of the biologic medication’s
cost paid by patient. Multivariate linear regression models of
MPR and proportional hazard models of persistence estimated
the impact of cost, adjusting for insurance type and demographic
and clinical variables. RESULTS: OOP expenditure averaged $8
per week (SD $14, range $0 to $127). Only a very small pro-
portion of patients (3.9%) paid more than $50 per week. The
mean (SD) MPR for all patients was 0.52 (0.31). Adherence sig-
niﬁcantly decreased with increased weekly OOP (Coeff −0.0035,
P < 0.0001) and when patients paid a higher proportion of
therapy costs (Coeff −0.8890, P < 0.0001). This translates into
approximately one week of therapy lost for every $5.50 increase
in weekly OOP. Adherence was lower for younger patients,
women and those with more comorbidities. Patients whose
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weekly cost exceeded $50 were more likely to discontinue than
patients with lower costs (HR 1.59, P < 0.001). CONCLUSION:
The majority of patients have very reasonable OOP for biolog-
ics. However, a small number of patients are burdened with high
OOP costs. The adverse impact of high OOP on adherence and
persistence needs to be considered when making decisions about
increasing co-pays.
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OBJECTIVES: Rheumatoid Arthritis (RA) imposes a signiﬁcant
burden of disease to both affected patients and the society as a
whole. We performed the ﬁrst German claims database analysis
among members of a statutory health insurance fund to estimate
RA treatment prevalence, to describe prescription patterns and
assess overall disease burden. METHODS: We based our analy-
sis on billing data from the years 2000 to 2004 of a German
sickness fund covering 1.5 million beneﬁciaries. RA patients
were identiﬁed by either inpatient or sick leave records due to
ICD-10 codes (M05, M06) or at least two prescriptions of a
disease-modifying drug (DMARD) or a TNF-α inhibitor. We
excluded patients with a variety of co-medications and diag-
noses, e.g. Psoriasis, Crohn’s Disease and malignant disease. We
speciﬁed treatment prevalence and patterns of RA disease man-
agement with DMARDs and TNFs in the selected population.
RESULTS: Out of the 728,111 beneﬁciaries continuously
enrolled between 2000 and 2004 n = 5850 (mean age: 43 ± 14
years) fulﬁlled the inclusion criteria for RA. RA treatment preva-
lence, standardized to the general German population was
0.68% for men and 1.25% for women. 43% of the patients with
RA were treated with DMARDs and 3.2% received TNF-α
inhibitors. 26% of RA-patients were initiated on DMARD
therapy by a general practitioner. Compared to the RA popula-
tion as a whole patients receiving TNF-α inhibitors were char-
acterized by a 2.6 fold number of sick leaves and a 6.4 fold
number of hospitalizations in the year prior to therapy initiation.
CONCLUSION: The RA treatment prevalence found in this
study is in line with local epidemiological research. As less than
half of RA-patients had a prescription of a DMARD, this may
indicate that therapeutic standards are not met. TNF-α inhibitors
are mainly prescribed in a high burden RA subpopulation.
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OBJECTIVES: The purpose of this study was to evaluate the
impact of specialty pharmacy prior authorization (SPA) program
on prescription costs for the biologic response modiﬁers
(Amevive, Enbrel, Humira, Kineret, Raptiva, and Remicade)—a
new class of medication for the treatment of several disease states
such as Rheumatoid Arthritis. METHODS: Prescription data
were obtained from a pharmacy beneﬁt manager’s pharmacy
claims database. This study used a retrospective case-control
one-to-one matching approach based on patient age, gender, and
client characteristics including the number of eligible members,
client type and region. The case clients had enrolled in the SPA
program in January 2005 and had remained part of the program
by December 31, 2005. Clients whose members did not use the
biologic response modiﬁers were excluded from the study. Per
eligible member per month (PMPM) total costs was the outcome
measured. RESULTS: The average PMPM total, plan and
member costs were $1.33, $1.30, and $0.03 in the case group,
while the average PMPM total, plan and member costs were
$1.51, $1.47 and $0.04 in the control group. Clients who imple-
mented a specialty pharmacy prior authorization program for
the biologic response modiﬁers saved an estimated PMPM total
cost of $0.18. CONCLUSION: Implementing a specialty phar-
macy prior authorization program reduced prescription drug
costs for the biologic response modiﬁers.
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OBJECTIVES: A major component of the economic burden
associated with the treatment of arthritis relates to surgical joint
replacement of the hips or knees. The objective of this study is
to compare the burden of hip/knee replacements performed in
the U.S. in the year 2000 and 2004. METHODS: The Health
care Cost and Utilization Project—National Inpatient Survey”
(HCUP-NIS) was analyzed to estimate the changes in the burden
of hip and knee replacements in the U.S. The HCUP itself is a
compilation of billing data which can yield estimates of national
hospital charges as well as the total number of hip and knee
replacement procedures. In 2004, the HCUP-NIS database con-
tained nearly 8 million records from about 1000 hospitals. The
ICD-9-CM procedure codes used in identifying patients are
81.51 (total hip replacement) and 81.54 (Total/partial knee
replacement). RESULTS: In the year 2004, approximately
225,900 total hip replacement and 431,458 total knee replace-
ment procedures were performed in the U.S. This is a 37%
increase in hip replacement procedures and a 53% increase in
total knee replacements compared to the year 2000 (164,458
total hip replacement and 281,534 total knee replacement). In
terms of economic burden, the national bill of hospital charges
increased by 111% (from $10.8 billion in year 2000 to $22.9
billion in year 2004). CONCLUSION: The data shows a steep
increase in the burden of joint replacements. Not considering pre
and post-operation care, the estimated hospital charges for joint
replacements alone were nearly 22.9 billion dollars in the United
States during the year 2004. This data, however, does not
provide reasons of steep increase in the burden of joint replace-
ments during this four year period. Further study is needed to
address these issues.
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OBJECTIVES: The introduction of tumor necrosis factor (TNF)
inhibitors such as etanercept and inﬂiximab has represented a
critical advance in the available treatments for patients with
Ankylosing Spondylitis (AS). Several clinical studies have shown
superior efﬁcacy of TNF inhibitors, but high costs and infrequent
instances of serious adverse side effects ask for priority setting.
The aim of this review was to identify and summarize the phar-
